[1] 黎籽秀, 刘博, 徐凌丽, 等. 高通量测序数据分析和临床诊断流程的解读. 中国循证儿科杂志, 2015, 10(1): 19-24.
[2] REISS J, LENZ U, AQUAVIVA-BOURDAIN C, et al. A GPHN point mutation leading to molybdenum cofactor deficiency. Clin Genet, 2011, 80(6): 598-599.
[3] REISS J, GROSS-HARDT S, CHRISTENSEN E, et al. A mutation in the gene for the neurotransmitter receptor-clustering protein gephyrin causes a novel form of molybdenum cofactor deficiency. Am J Hum Genet, 2001, 68(1): 208-213.
[4] LIONEL A C, VAAGS A K, SATO D, et al. Rare exonic deletions implicate the synaptic organizer Gephyrin (GPHN) in risk for autism, schizophrenia and seizures. Hum Mol Genet, 2013, 22(10): 2055-2066.
[5] ZHANG X, VINCENT A S, HALLIWELL B, et al. A mechanism of sulfite neurotoxicity: direct inhibition of glutamate dehydrogenase. J Biol Chem, 2004, 279(41): 43035-43045.
[6] BELAIDI A A, ARJUNE S, SANTAMARIA-ARAUJO JA, et al. Molybdenum cofactor deficiency: a new HPLC method for fast quantification of s-sulfocysteine in urine and serum. JIMD Rep, 2012, 5: 35-43.
[7] MECHLER K, MOUNTFORD W K, HOFFMANN G F, et al. Ultra-orphan diseases: a quantitative analysis of the natural history of molybdenum cofactor deficiency. Genet Med, 2015, 17(12): 965-970.
[8] ALONZO M M, CAZORLA E, CANOVAS E, et al. Molybdenum cofactor deficiency: Mega cisterna magna in two consecutive pregnancies and review of the literature. Appl Clin Genet, 2020, 13: 49-55.
[9] ARICAN P, GENCPINAR P, KIRBIYIK O, et al. The clinical and molecular characteristics of molybdenum cofactor deficiency due to MOCS2 mutations. Pediatr Neurol, 2019, 99: 55-59.
[10] SCELSA B, GASPERINI S, RIGHINI A, et al. Mildphenotype in Molybdenum cofactor deficiency: A new patient and review of the literature. Mol Genet Genomic Med, 2019, 7(6): e657.
[11] NAGAPPA M, BINDU P S, TALY A B, et al. Child Neurology: Molybdenum cofactor deficiency. Neurology, 2015, 85(23): e175-e178.
[12] HIGUCHI R, SUGIMOTO T, TAMURA A, et al. Early features in neuroimaging of two siblings with molybdenum cofactor deficiency. Pediatrics, 2014, 133(1): e267-e271.
[13] SASS J O, GUNDUZ A, ARAUJO R F C, et al. Functional deficiencies of sulfite oxidase: Differential diagnoses in neonates presenting with intractable seizures and cystic encephalomalacia. Brain Dev, 2010, 32(7): 544-549.
[14] KIKUCHI K, HAMANO S, MOCHIZUKI H, et al. Molybdenum cofactor deficiency mimics cerebral palsy: differentiating factors for diagnosis. Pediatr Neurol, 2012, 47(2): 147-149.
[15] LUBOUT C, DERKS T, MEINERS L, et al. Molybdenum cofactor deficiency type A: Prenatal monitoring using MRI. Eur J Paediatr Neurol, 2018, 22(3): 536-540.
[16] SCHWAHN B C, VAN SPRONSEN F J, BELAIDI A A, et al. Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. Lancet, 2015, 386(10007): 1955-1963. |
